Do analysts prefer ATYR or ACB?

aTyr Pharma currently has a consensus target price of $17.00, indicating a potential upside of 2,927.60%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, ATYR or IMDX?

Oncocyte has higher revenue and earnings than aTyr Pharma. Oncocyte is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 289.76 -$74.12M -$0.73 N/A Oncocyte $4.05M 42.89 -$50.22M -$1.48 N/A

Is ATYR or IMDX more profitable?

aTyr Pharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Oncocyte -2,454.64% N/A -96.96%

Is TTRX or ATYR more profitable?

Turn Therapeutics' return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A aTyr Pharma N/A -100.14% -73.55%

aTyr Pharma (ATYR) Competitors

$0.56 +0.02 (+4.54%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$0.58 +0.02 (+3.12%)

As of 06/24/2026 07:54 PM Eastern

Compare

ATYR vs. ACB, DTIL, IMDX, TTRX, and PLX

Should you buy aTyr Pharma stock or one of its competitors? MarketBeat compares aTyr Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with aTyr Pharma include Aurora Cannabis (ACB), Precision BioSciences (DTIL), Oncocyte (IMDX), Turn Therapeutics (TTRX), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry.

How does aTyr Pharma compare to Aurora Cannabis?

aTyr Pharma (NASDAQ:ATYR) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Aurora Cannabis had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 equaled Aurora Cannabis'average media sentiment score.

Company	Overall Sentiment
aTyr Pharma	Neutral
Aurora Cannabis	Neutral

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

aTyr Pharma has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	289.76	-$74.12M	-$0.73	N/A
Aurora Cannabis	$247.82M	0.70	-$88.13M	-$1.56	N/A

aTyr Pharma has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Aurora Cannabis	-33.57%	0.10%	0.07%

aTyr Pharma has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

aTyr Pharma currently has a consensus target price of $17.00, indicating a potential upside of 2,927.60%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

aTyr Pharma beats Aurora Cannabis on 11 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Precision BioSciences' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
Precision BioSciences	Neutral
aTyr Pharma	Neutral

Precision BioSciences has higher revenue and earnings than aTyr Pharma. Precision BioSciences is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.08	-$45.72M	-$3.67	N/A
aTyr Pharma	$190K	289.76	-$74.12M	-$0.73	N/A

aTyr Pharma has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
aTyr Pharma	N/A	-100.14%	-73.55%

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Precision BioSciences has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Precision BioSciences currently has a consensus price target of $32.25, suggesting a potential upside of 378.49%. aTyr Pharma has a consensus price target of $17.00, suggesting a potential upside of 2,927.60%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

aTyr Pharma beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Oncocyte?

aTyr Pharma (NASDAQ:ATYR) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

aTyr Pharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Oncocyte	-2,454.64%	N/A	-96.96%

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncocyte has higher revenue and earnings than aTyr Pharma. Oncocyte is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	289.76	-$74.12M	-$0.73	N/A
Oncocyte	$4.05M	42.89	-$50.22M	-$1.48	N/A

aTyr Pharma has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

In the previous week, Oncocyte had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 1 mentions for Oncocyte and 0 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Overall Sentiment
aTyr Pharma	Neutral
Oncocyte	Neutral

aTyr Pharma presently has a consensus price target of $17.00, indicating a potential upside of 2,927.60%. Oncocyte has a consensus price target of $12.00, indicating a potential upside of 123.05%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe aTyr Pharma is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

aTyr Pharma beats Oncocyte on 10 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Turn Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 31.36%. aTyr Pharma has a consensus target price of $17.00, suggesting a potential upside of 2,927.60%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Turn Therapeutics had 2 more articles in the media than aTyr Pharma. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.36 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
aTyr Pharma	Neutral

Turn Therapeutics' return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
aTyr Pharma	N/A	-100.14%	-73.55%

Turn Therapeutics has higher earnings, but lower revenue than aTyr Pharma. Turn Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
aTyr Pharma	$190K	289.76	-$74.12M	-$0.73	N/A

61.7% of aTyr Pharma shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

aTyr Pharma beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

How does aTyr Pharma compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

aTyr Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
aTyr Pharma	N/A	-100.14%	-73.55%

Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 435.71%. aTyr Pharma has a consensus price target of $17.00, suggesting a potential upside of 2,927.60%. Given aTyr Pharma's higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Protalix BioTherapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.36	$8.31M	$0.18	12.44
aTyr Pharma	$190K	289.76	-$74.12M	-$0.73	N/A

In the previous week, Protalix BioTherapeutics' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
aTyr Pharma	Neutral

Summary

Protalix BioTherapeutics and aTyr Pharma tied by winning 7 of the 14 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.66M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.77	20.50	25.39	23.96
Price / Sales	289.76	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.81	8.26	10.76	6.41
Net Income	-$74.12M	$23.91M	$3.56B	$337.14M
7 Day Performance	24.64%	2.12%	0.98%	-1.06%
1 Month Performance	14.59%	2.40%	0.78%	0.49%
1 Year Performance	-89.01%	57.09%	30.24%	28.43%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	3.1378 of 5 stars	$0.56 +4.5%	$17.00 +2,927.6%	-89.4%	$52.66M	$190K	N/A	53	Gap Down
ACB Aurora Cannabis	0.3319 of 5 stars	$2.87 -2.0%	N/A	-28.9%	$176.06M	$320.59M	N/A	1,028
DTIL Precision BioSciences	1.8952 of 5 stars	$7.08 +4.0%	$32.25 +355.5%	+47.5%	$175.71M	$34.26M	N/A	200	Positive News
IMDX Oncocyte	1.9254 of 5 stars	$5.40 -0.7%	$12.00 +122.2%	N/A	$175.66M	$4.05M	N/A	120
TTRX Turn Therapeutics	2.2049 of 5 stars	$5.77 -1.7%	$8.00 +38.6%	N/A	$174.86M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. ACB, DTIL, IMDX, TTRX, and PLX

How does aTyr Pharma compare to Aurora Cannabis?

Summary

How does aTyr Pharma compare to Precision BioSciences?

Summary

How does aTyr Pharma compare to Oncocyte?

Summary

How does aTyr Pharma compare to Turn Therapeutics?

Summary

How does aTyr Pharma compare to Protalix BioTherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. ACB, DTIL, IMDX, TTRX, and PLX

How does aTyr Pharma compare to Aurora Cannabis?

Does the media refer more to ATYR or ACB?

Do institutionals & insiders hold more shares of ATYR or ACB?

Which has preferable earnings & valuation, ATYR or ACB?

Is ATYR or ACB more profitable?

Which has more risk and volatility, ATYR or ACB?

Do analysts prefer ATYR or ACB?

Summary

How does aTyr Pharma compare to Precision BioSciences?

Does the media prefer DTIL or ATYR?

Which has preferable valuation & earnings, DTIL or ATYR?

Is DTIL or ATYR more profitable?

Do institutionals and insiders hold more shares of DTIL or ATYR?

Which has more volatility and risk, DTIL or ATYR?

Do analysts prefer DTIL or ATYR?

Summary

How does aTyr Pharma compare to Oncocyte?

Is ATYR or IMDX more profitable?

Do institutionals & insiders believe in ATYR or IMDX?

Which has better valuation and earnings, ATYR or IMDX?

Which has more volatility and risk, ATYR or IMDX?

Does the media favor ATYR or IMDX?

Do analysts recommend ATYR or IMDX?

Summary

How does aTyr Pharma compare to Turn Therapeutics?

Do analysts rate TTRX or ATYR?

Does the media prefer TTRX or ATYR?

Is TTRX or ATYR more profitable?

Which has higher valuation & earnings, TTRX or ATYR?

Do institutionals & insiders have more ownership in TTRX or ATYR?

Summary

How does aTyr Pharma compare to Protalix BioTherapeutics?

Do institutionals and insiders have more ownership in PLX or ATYR?

Is PLX or ATYR more profitable?

Do analysts prefer PLX or ATYR?

Which has more volatility & risk, PLX or ATYR?

Which has higher valuation and earnings, PLX or ATYR?

Does the media refer more to PLX or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools